Maggot therapy returns as doctors use larvae to heal stubborn wounds

Why doctors are turning back to maggots

Sterile larvae are being used to treat wounds that have stalled because they can do something many standard therapies struggle to do well: eat dead tissue without damaging healthy tissue. In modern wound care, these are the medical grade larvae of the green bottle fly, Lucilia sericata, historically known as Phaenicia sericata, and they are applied deliberately, not accidentally, to stubborn wounds.

The treatment is called maggot debridement therapy, larval therapy, or biosurgery. Its modern appeal lies in its practicality: when wounds are clogged with necrotic tissue, bacteria, and debris, the larvae can help clear the wound bed, reduce the bacterial burden, and encourage granulation tissue to form. That makes the therapy less a curiosity than a targeted tool for difficult cases.

How the therapy works

In the United States, Medical Maggots were cleared by the U.S. Food and Drug Administration in January 2004 as a prescription-only medical device. The FDA-cleared use is for debriding non-healing necrotic skin and soft-tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.

The dressing is designed to keep the medical grade larvae on the wound during the debridement period and then allow easy, controlled removal when the patient and therapist decide the larvae have finished their work. That controlled design matters. This is not an uncontrolled infestation, but a regulated clinical procedure with a defined endpoint and a specific wound-care goal.

Monarch Labs describes its Medicinal Maggots as regulated by the FDA as a prescription-only medical device, and the company says they were the first living organism ever allowed by the FDA for production and marketing as a prescription medical device. The point is not novelty for its own sake. The point is that a living treatment can be manufactured, standardized, and used under medical supervision when the wound demands a different approach.

Where maggot therapy fits in wound care

Maggot therapy is not meant to replace every other wound treatment. It is most useful when conventional debridement, surgery, or antibiotics have not solved the problem, or when a lower-tech option is preferable. That makes it especially relevant in complex, chronic wounds where dead tissue keeps returning and the wound bed never fully resets.

The therapy has deep roots. It has been used for centuries in traditional and battlefield medicine, then declined after antibiotics became the dominant medical answer to infection and wound care. Its return in the 21st century reflects a broader recognition that not every hard wound responds to the same modern toolkit, and that some older methods still have a place when used carefully and scientifically.

What the evidence actually shows

The best evidence for maggot therapy is not about spectacle, but about speed and wound preparation. Systematic reviews conclude that it can accelerate debridement, support granulation tissue development, and reduce wound surface area. That is a meaningful clinical gain, especially for wounds that have been stuck for weeks or months.

The evidence for complete healing is less certain. In other words, the larvae are better supported as a way to prepare a wound and move it toward healing than as a guaranteed final fix. That distinction matters for patients and clinicians alike, because the therapy’s value often comes earlier in the wound-care pathway, when the goal is to get a chronic wound moving again rather than promise a cure.

A narrative review on barriers to maggot debridement therapy describes it as underused and potentially very effective compared with conventional treatments. That gap between promise and practice is not mostly a medical failure. It is often a human one.

Why chronic wounds are a public-health issue

The case for revisiting maggot therapy becomes clearer when you look at the scale of chronic wounds. A 2025 compendium describes chronic wounds as a silent epidemic in the United States, affecting about one in six Medicare beneficiaries, or roughly 10.5 million people. The same source estimates the annual Medicare cost at $22.5 billion.

Those numbers help explain why a treatment that sounds old-fashioned can still matter in a modern health system. Chronic wounds are expensive, slow, painful, and vulnerable to infection. They drive repeat clinic visits, prolonged care, and serious complications, and they also reflect larger inequities in access to timely wound management, specialized providers, and sustained follow-up.

For patients living with pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, or non-healing surgical wounds, the burden is not abstract. These wounds can limit mobility, disrupt work and caregiving, and create a cycle in which healing is delayed precisely because treatment is difficult to access or maintain.

The stigma is part of the treatment barrier

Even when the science is promising, the image of maggots can stop people before they start. Reviews repeatedly note that disgust and stigma remain major barriers to wider use of maggot debridement therapy. For many patients, the first reaction is fear of being contaminated rather than relief that a wound might finally be cleaned.

That is why framing matters. Studies and reviews note that acceptance often improves when the therapy is presented as a controlled medical procedure instead of an infestation. The difference is not cosmetic. It shapes whether patients can tolerate the idea long enough to benefit from a treatment that may help where other options have stalled.

The stigma also raises a larger health-equity question: therapies that are cheap, effective, and low-tech do not automatically spread just because they work. They have to be explained, normalized, and integrated into care systems that are often shaped by habit, reimbursement, and cultural discomfort.

What this revival means for wound care

Maggot therapy’s comeback is less a return to the past than a reminder that wound care still needs flexible tools. Sterile larvae of Lucilia sericata are not a last-resort gimmick. They are an FDA-cleared, prescription-only device that can help remove dead tissue, prepare a wound bed, and support healing when standard methods fall short.

The strongest case for the therapy is practical and public-minded at once: chronic wounds are common, costly, and devastating, and some of the most useful solutions are not the most familiar ones. In that setting, the humble larva becomes something unusual in modern medicine, a living treatment with enough evidence to justify a second look.